v3.26.1
Share-Based Compensation
3 Months Ended
Mar. 31, 2026
Share-Based Compensation [Abstract]  
Share-Based Compensation

12. Share-Based Compensation

 

2024 Equity Incentive Plan

 

The Company’s 2024 Equity Incentive Plan (the “2024 Plan”) became effective at the Closing Date. As of March 31, 2026, 297,319 shares of common stock were available for issuance under the 2024 Plan. The initial number of shares authorized for issuance under the 2024 Plan was 208,026. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024 Plan reserve will automatically increase in an amount equal to the lesser of (a) 5% of the number of shares of the Company’s common stock outstanding on December 31 of the preceding year and (b) a number of shares of common stock determined by the Company’s board of directors. As a result, the number of shares authorized for issuance under the 2024 Plan increased by 136,663 on January 1, 2026.

 

Under the 2024 Plan, the Company can grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees.

2014 Stock Incentive Plan

 

The 2014 Stock Incentive Plan (the “2014 Plan”) of Legacy Abpro expired as of the Closing Date, in accordance with its original terms. As a result of the expiration, no further awards may be granted under the 2014 Plan. As of March 31, 2026, there were 184,141 options outstanding under the 2014 Plan. Stock options granted to employees and directors typically vest over four years. Stock options granted to non-employees typically vest immediately at the grant date. The maximum contractual term of the stock options is ten years.

 

The Company granted restricted stock units (“RSUs”) to various employees and directors under the 2014 Plan. These RSUs cliff vested on the first anniversary of the grant date.

 

Stock Options

 

The summary of the Company’s stock option activity is as follows:

 

  

Number of

Stock

Options

  

Weighted-
Average

Exercise
Price

  

Weighted-
Average

Remaining

Contractual Life

 
Outstanding at December 31, 2025   217,549   $50.24    4.0 
Granted   
    
    
 
Exercised   
    
    
 
Forfeited/Expired/Cancelled   (25,328)  $51.38    
 
Outstanding at March 31, 2026   192,221   $49.70    4.2 
Exercisable at March 31, 2026   192,217   $49.69    4.2 

 

Restricted Stock Units

 

The summary of the Company’s restricted stock unit activity is as follows:

 

   Number
of
Shares
   Weighted-
Average
Grant Date
Fair Value
   Weighted-
Average
Remaining
Vesting
Period
 
Outstanding at December 31, 2025   31,169   $7.78    1.4 
Granted   
    
    
 
Vested   (6,666)  $8.85    
 
Forfeited   
    
    
 
Outstanding at March 31, 2026   24,503   $7.49    1.5 

 

As of March 31, 2026, 6,808 RSUs were vested in accordance with their terms, but the shares of common stock were not issued to the holders.

 

On October 22, 2024, the Company’s board of directors authorized the issuance of 20,449 RSUs to the Company’s employees and a Board member, however no awards were issued until the fourth quarter of 2025. The Company expensed the fair value of the authorized RSU on a straight-line basis over their vesting period. In December 2025, the Company issued the RSUs to these employees with different terms. The issuance of the RSUs was accounted for as a modification with $396 RSU liability accrued through the issuance date reclassified into additional paid-in capital. As the fair value of the awards issued was less than the fair value of the promised awards, the Company continued to recognize share-based compensation based on the grant date fair value in accordance with ASC 718-20-35-3(b), which states that total recognized compensation cost for an equity award shall at least equal the fair value of the award at the grant date. For the three months ended March 31, 2026 and 2025, the Company recorded $245 and $204, respectively, in share-based compensation expense related to these authorized awards.

Share-Based Compensation Expense

 

The summary of the recorded share-based compensation expense is as follows:

 

   Three months ended
March 31,
 
   2026   2025 
         
Research and development  $
-
   $10 
General and administrative   302    502 
Total stock-based compensation  $302   $512 

 

As of March 31, 2026, there was no unrecognized compensation cost related to stock option awards. As of March 31, 2026, there was approximately $2,091 of unrecognized compensation cost related to unvested restricted stock awards that are expected to be recognized over a weighted-average period of 1.4 years.